Halda Therapeutics

Halda Therapeutics was a clinical-stage biotechnology company and Yale University spinout developing oral, targeted cancer therapies built on its proprietary RIPTAC (Regulated Induced Proximity TArgeting Chimera) platform, a novel "hold and kill" modality for the precision treatment of solid tumors. Its lead program, HLD-0915, is a first-in-class oral RIPTAC therapeutic in development for metastatic castration-resistant prostate cancer (mCRPC), with earlier-stage candidates spanning breast, lung, and other tumor types. Backed by investors including Canaan Partners, Halda was acquired by Johnson & Johnson in 2025 for approximately $3.05 billion in cash, with its platform folded into Johnson & Johnson Innovative Medicine's oncology pipeline. As a therapeutics developer, Halda operated no public developer platform, API, or documentation surface; this profile is maintained in the API Evangelist network as a company identity and portfolio-graph record rather than an API producer.

Halda Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Cancer Therapeutics.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsOncologyCancer TherapeuticsProstate CancerDrug DiscoveryLife SciencesYale Spinout

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/halda-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: halda-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/halda-therapeutics.png
name: Halda Therapeutics
description: Halda Therapeutics was a clinical-stage biotechnology company and Yale University spinout developing oral, targeted
  cancer therapies built on its proprietary RIPTAC (Regulated Induced Proximity TArgeting Chimera) platform, a novel "hold
  and kill" modality for the precision treatment of solid tumors. Its lead program, HLD-0915, is a first-in-class oral RIPTAC
  therapeutic in development for metastatic castration-resistant prostate cancer (mCRPC), with earlier-stage candidates spanning
  breast, lung, and other tumor types. Backed by investors including Canaan Partners, Halda was acquired by Johnson & Johnson
  in 2025 for approximately $3.05 billion in cash, with its platform folded into Johnson & Johnson Innovative Medicine's oncology
  pipeline. As a therapeutics developer, Halda operated no public developer platform, API, or documentation surface; this
  profile is maintained in the API Evangelist network as a company identity and portfolio-graph record rather than an API
  producer.
url: https://raw.githubusercontent.com/api-evangelist/halda-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: johnson-and-johnson
x-acquisition-value-usd: '3050000000'
x-acquisition-year: '2025'
x-industry: biotechnology
x-no-api-surface: 'true'
x-enrichment-note: 'Enrichment 2026-07-19: haldatx.com now redirects to jnj.com/innovativemedicine following the Johnson &
  Johnson acquisition. No public API, developer portal, documentation, SDK, or technical surface exists (searched). Identity-only
  enrichment; no API artifacts produced (no fabrication).'
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Oncology
- Cancer Therapeutics
- Prostate Cancer
- Drug Discovery
- Life Sciences
- Yale Spinout
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence